Gemphire Therapeutics Inc. (GEMP) Is Up Sharply On Study Results
Markets2018-06-29
9 Views
Gemphire Therapeutics Inc. (GEMP) announced after the bell Thursday that its Phase 2b trial of gemcabene met its primary endpoint.
Source: RTTNews
The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.
Sarepta Therapeutics, Inc. (Nasdaq: SRPT) to Share Clinical Update from SRP-9003 Gene Therapy Trial to Treat Limb-girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy
